

SKYEPHARMA PLC  
Form 6-K  
May 07, 2004

**SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a - 16 OR 15d - 16 OF  
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of May, 2004

SkyePharma PLC

---

(Translation of registrant's name into English)

SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England

---

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.

Form 20-F  Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-  
\_\_\_\_\_

---

For Immediate Release

**SkyePharma PLC ("the Company")**

7 May 2004

**Notification of Major Interest in Shares**

In accordance with the Companies Act 1985 (as amended) the Company was informed today that on 6 May 2004 Standard Life Investments, on behalf of the Standard Life Group, sold 727,259 SkyePharma plc Ordinary Shares, thus decreasing their holding to 30,797,711 Ordinary Shares, representing 4.98% of the issued share capital of the Company. These Ordinary Shares are registered in the name of Stanlife Nominees Limited.

- e n d s -

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**SkyePharma PLC**

By: /s/ Douglas Parkhill

Name: Douglas Parkhill

Title: Company Secretary

Date: May, 2004